Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug

Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug

Source: 
Endpoints
snippet: 

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.